Page last updated: 2024-12-06

2,2'-dipicolylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,2'-dipicolylamine (DPA) is a bidentate ligand that has been widely studied in coordination chemistry. It is synthesized by the reaction of 2-picoline with formaldehyde and ammonia. DPA has been shown to form stable complexes with a variety of metal ions, including copper, zinc, and nickel. These complexes have been investigated for their potential applications in catalysis, materials science, and medicine. For instance, DPA-copper complexes have been shown to be effective catalysts for a variety of organic reactions. DPA-zinc complexes have been investigated for their potential use in the development of new luminescent materials. DPA-nickel complexes have been shown to exhibit antitumor activity in vitro. The study of DPA is important because it provides insights into the fundamental principles of coordination chemistry and because it leads to the development of new materials and technologies.'

2,2'-dipicolylamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73759
CHEMBL ID1650627
SCHEMBL ID230222
MeSH IDM0486712

Synonyms (56)

Synonym
nsc 176070
unii-p978wad4kk
n-(2-pyridylmethyl)pyridine-2-methylamine
pyridine, 2,2'-(iminodimethylene)di-
einecs 216-266-8
p978wad4kk ,
2-pyridinemethanamine, n-(2-pyridinylmethyl)-
pyridine,2'-(iminodimethylene)di-
nsc-176070
2,2'-dipicolylamine
bis(2-pyridylmethyl)amine
1539-42-0
nsc176070
bis-(2-picolyl)amine
di-(2-picolyl)amine, 97%
AKOS000243641
1-pyridin-2-yl-n-(pyridin-2-ylmethyl)methanamine
alpha,alpha'-iminodi(2-picoline)
D2228
1-(2-pyridinyl)-n-(2-pyridinylmethyl)methanamine
A809479
CHEMBL1650627
bis(pyridin-2-ylmethyl)amine
bis-2-picolylamine
di-(2-picolyl)amine
bis((pyridin-2-yl)methyl)amine
picolylamine (bis-2-)
pyridinemethanamine, n-(pyridinylmethyl)-
29227-68-7
SCHEMBL230222
dipicolylamine
di(2-picolyl)amine
di-(2-picolyl)-amine
DTXSID8061767
J-519890
CS-W008808
n-(2-pyridinylmethyl)-2-pyridinemethanamine
mfcd00129044
GS-6736
2,2'-bis(pyridylmethyl)amine
bis[(pyridin-2-yl)methyl]amine
J-009057
2,2/'-dipicolylamine
F0001-0548
2,2-dipicolylamine
bispicolylamine
BCP05347
SY004180
FT-0756841
Q19903962
AMY30541
bis(2-pyridylmethyl) amine
dpa, dipicolylamine-
n,n-bis(pyridin-2-ylmethyl)amine
SB52257
EN300-76228
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1632917Metal chelating activity assessed as compound-Zn2+ complex formation at 50 uM after 15 mins by spectrofluorimetric analysis2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Dual action Smac mimetics-zinc chelators as pro-apoptotic antitumoral agents.
AID1182272Protection against 40 uM zinc-acetate-induced inhibition of LYP (unknown origin) at 80 uM incubated for 30 mins at 25 degC before addition of DiFMUP substrate2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID1632922Metal chelating activity assessed as compound-Zn2+ complex formation2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Dual action Smac mimetics-zinc chelators as pro-apoptotic antitumoral agents.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1182270Inhibition of LYP (unknown origin) at 20 to 100 uM incubated for 30 mins at 25 degC before addition of DiFMUP substrate2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1672121Metal chelating activity assessed as Cu2+-compound complex formation by measuring binding constant in 0.1 M KNO3 at 25 degreeC2019European journal of medicinal chemistry, Apr-15, Volume: 168Inhibiting Aβ toxicity in Alzheimer's disease by a pyridine amine derivative.
AID1672122Metal chelating activity assessed as Zn2+-compound complex formation by measuring binding constant in 0.1 M KNO3 at 25 degreeC2019European journal of medicinal chemistry, Apr-15, Volume: 168Inhibiting Aβ toxicity in Alzheimer's disease by a pyridine amine derivative.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (113)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (16.81)29.6817
2010's81 (71.68)24.3611
2020's13 (11.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.83 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other111 (98.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]